Haemonetics (HAE) EBITDA (2009 - 2026)

Haemonetics has reported EBITDA for 18 years, with the latest figure at $57.5 million in Q2 2026.

• On a quarterly basis, EBITDA rose 6.66% year-over-year to $57.5 million in Q2 2026; TTM through Jun 2026 was $160.3 million, a 32.05% decrease from a year earlier, with the FY2026 full-year figure at $156.7 million, down 29.34% from the prior year.
• EBITDA was $57.5 million for Q2 2026 at Haemonetics, up from -$23.0 million in the prior quarter.
• The five-year high for EBITDA was $71.3 million in Q1 2025, with the low at -$23.0 million in Q1 2026.
• Average EBITDA over 5 years is $42.7 million, with a median of $46.0 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2026: EBITDA jumped 2113.45% in 2022, then sank 132.28% in 2026.
• Over 5 years, EBITDA stood at $43.3 million in 2022, then climbed by 6.24% to $46.0 million in 2023, then rose by 28.39% to $59.0 million in 2024, then climbed by 14.17% to $67.4 million in 2025, then decreased by 14.75% to $57.5 million in 2026.
• The last three EBITDA figures came in at $57.5 million (Q2 2026), -$23.0 million (Q1 2026), and $67.4 million (Q4 2025), per Business Quant data.